辉瑞 Investor-Overview-at-2025-JPM-vFINAL.pdf

1、1Pfizer Investor OverviewAt 2025 J.P.Morgan Healthcare ConferenceJanuary 20252These materials will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.We inc

2、lude forward-looking statements about,among other topics,our anticipated operating and financial performance,including financial guidance and projections;changes to Pfizers commercial organization;reorganizations;business plans,strategy,goals and prospects;expectations for our product pipeline,in-li

3、ne products and product candidates,including anticipated regulatory submissions,data read-outs,study starts,approvals,launches,clinical trial results and other developing data,revenue contribution and projections,potential pricing and reimbursement,potential market dynamics,including demand,market s

4、ize and utilization rates and growth,performance,timing of exclusivity and potential benefits;strategic reviews;capital allocation objectives;an enterprise-wide cost realignment program(including anticipated costs,savings and potential benefits);a manufacturing optimization program to reduce our cos

5、t of goods sold(including anticipated costs,savings and potential benefits);dividends and share repurchases;plans for and prospects of our acquisitions,dispositions and other business development activities,including our December 2023 acquisition of Seagen,and our ability to successfully capitalize

6、on growth opportunities and prospects;manufacturing and product supply;our ongoing efforts to respond to COVID-19,including our plans and expectations regarding our COVID-19 products and our expectations regarding the impact of COVID-19 on our business,operations and financial results;and other stat